ENO2 and lung carcinoma: Serological markers such as Carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and Cyfra 21-1 are serological markers used for the monitoring of treatment response in lung cancer patients, but their application as screening biomarkers is still a challenging question [17–19].